Nanoviricides (Nanoviricides) Growth Rank : 0 (As of May. 27, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Growth Rank?

Nanoviricides has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Nanoviricides Growth Rank Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoviricides (Nanoviricides) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Executives

Makarand Jawadakar	director	C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day	director	C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk	director	C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan	director, 10 percent owner, officer: President	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni	director	C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas	officer: Chief Financial Officer	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour	director, 10 percent owner	666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc.	10 percent owner	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516